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Local delivery of chemotherapeutic drugs has long been recognized as a potential method for reaching high drug doses at the
target site while minimizing systemic exposure. Cisplatin is one of the most eﬀective chemotherapeutic agents for the treatment
of various tumors; however, its systemic toxicity remains the primary dose-limiting factor. Here we report that incorporation of
cisplatin into a fatty acid-based polymer carrier followed by a local injection into the solid tumor resulted in a successful tumor
growth inhibition in heterotopic mouse bladder tumor model in mice. Platinum concentration in the tumor tissue surrounding
the injected implant remained above the therapeutic level up to 14 days after the injection, while the plasma levels were several
orders of magnitude lower comparing to systemic delivery. The reported delivery system increased the maximum tolerated dose
of cisplatin 5 times compared to systemic delivery, thus potentially improving antitumor eﬃcacy of cisplatin in solid tumor
model.
1.Introduction
Polymer-based gels are potential carriers that may aﬀect a
target tumor while reducing the toxic eﬀects of the loaded
drug. Speciﬁcally, we suggest that it is possible to optimize
theirdeliveryandimprovetheresponsivenessofsolidtumors
to current chemotherapeutic agents [1].
Cisplatin is widely used for the treatment of testicular,
bladder, head and neck, small-cell and non-small-cell lung
cancers, but it also possesses substantial side eﬀects, such
as nephro-, neuro-, and myelotoxicity [2–4]. Polymer-based
cisplatin-loaded drug delivery systems such as liposomes [5],
polymeric micelles [6], hydrogels [7], polymeric gels [8],
and implants [9] provide an opportunity to deliver high,
localized doses of drugs for a prolonged period directly
into a tumor or at the site of tumor resection. Implanting
a biodegradable device loaded with antineoplastic agent in
the cavity created by the tumor removal provides high local
concentration of the drug, killing the surviving malignant
cells. This may also prevent the systemic side eﬀects of
chemotherapy that is normally associated with intravenous
administration.Injectabledevicemayalsoprovidesustained,
controlled delivery of the drug to the malignant tumor.
In addition, clinicians can perform debulking of large
tumor prior to the surgery by exposing the tumor to large
concentrations of the drug [10].
Biodegradable polyanhydrides and polyesters are useful
materials for controlled drug delivery [11]. In earlier reports
we have described the synthesis and various applications
of ricinoleic acid-based polyanhydrides as drug carriers
[12, 13] .T h e s ep o l y m e r sh a v eh y d r o p h o b i cb a c k b o n e
with hydrolytically labile anhydride and/or ester that may2 Chemotherapy Research and Practice
hydrolyze to dicarboxylic acids and hydroxy acid monomers
when placed in aqueous medium. The toxicity, biodegra-
dation, and elimination of polyanhydrides and aliphatic
polyesters have been recently reviewed [14, 15]. The fatty
acid components of these polymers undergo extensive
metabolism in the body and are mainly excreted in the
form of carbon dioxide. The in vitro and in vivo toxicity
tests indicate that these polymers are well tolerated by the
tissues and can be generally considered as biocompatible
[14]. Furthermore, Vaisman et al. [16] evaluated the safety
and biocompatibility of ricinoleic acid-based polymer in
rats in high doses intramuscularly, subcutaneously, and
intracranially. No systemic tissue damage, polymer-related
lesions, or abnormalities could be detected in animals.
Herein we report the application of a biodegradable
poly (sebacic-co-ricinoleic) acid (P(SA:RA)) polymer for
local cisplatin delivery to the solid tumor. Cisplatin can be
incorporated by direct mixing with P(SA:RA), which is an
injectable fatty acid-based polymer that solidiﬁes in contact
with aqueous media [17, 18]. As a result the incorporated
drug is released in a sustained manner over a period of
days. We hypothesized that cisplatin released from the
polymer formulation injected directly in the solid tumor will
stop the tumor growth and result in a prolonged survival.
Furthermore, we investigated cisplatin local and systemic
distributionaftersingleintratumoralinjectioninheterotopic
mouse bladder tumor model.
2.MaterialsandMethods
2.1. Materials. Poly (sebacic acid-co-ricinoleic acid ester
anhydride) 2:8 and 3:7 were synthesized as previously
described [17]. Cisplatin was purchased from AlfaAesar
(MA, USA). All solvents were analytical grade from BioLab
(Jerusalem, Israel) or Frutarom (Haifa, Israel) and were used
without further puriﬁcation. MBT (mouse bladder tumor)
cells were a generous gift from Professor Ofer Gofrit [19]
from Hadassah Ein-Karem Hospital (Jerusalem, Israel). Cell
culture medium and fetal calf serum (FCS) were obtained
from Biological Industries (Beit-Haemek, Israel).
2.2. Preparation of Formulations and In Vitro Drug Release.
The formulations of P(SA:RA) 2:8 and 3:7 with 5%w/w
of cisplatin were prepared under sterile conditions by direct
mixing of the polymer with the drug at room temperature.
The composition was mixed until a smooth paste was
obtained.Allformulationswereasepticallyloadedinsyringes
and tested for sterility in TSB medium [20]. The obtained
formulations were injectable semisolid pastes at room
temperature. In vitro drug release studies were conducted
by injecting 20mg of the pasty formulations sample in a
50mL phosphate buﬀer solution (0.1M, pH 7.4) at 37◦C
with constant shaking (100RPM). The paste hardened to
a soft solid shortly after addition to the buﬀer. The release
medium was replaced periodically with fresh buﬀer solution,
and platinum concentration in the solution was determined
by Inductively Coupled Plasma Mass Spectrometry (ICP-
MS, Perkin Elmer SCIEX). The instrument is based on
Dynamic Reaction Cell technology (ELAN DRC II) with
performance-enhancing Axial Field technology. The validity
of the analytical procedure was established through a study
of speciﬁcity, precision, linearity, and accuracy. The linearity
of the analytical procedure was evaluated by plotting the
detector response (peak area) against analyte concentration.
Linear regression analysis was applied to calculate the slope,
intercept, and linear correlation coeﬃcient (R2). The limit
of detection (LOD) was calculated as signal-to-noise ratio
of 3:1, and the limit of the quantiﬁcation (LOQ) was
determined as signal-to-noise ratio of 10:1. The number of
points used in each curve was 6. Calibration curves were
obtained by programmed injection of diﬀerent aliquots (10–
45μL) of a standard solution with increments of 5μL. The
concentration of standard solutions was 10ppb of platinum
indoubledistilledwater,whilethelinearregionwasobserved
at concentration between 0.01 and 100ppb. All experiments
were performed in triplicate.
2.3. In Vitro Cytotoxicity. The MBT cells were maintained in
monolayer cultures in Dulbecco’s modiﬁed Eagle’s medium
containing10%(v/v)fetalcalfserumandsupplementedwith
200IU/mL penicillin and 200μL/mL streptomycin (Beit-
Haemek, Israel) in 75cm2 ﬂasks, in humidiﬁed 5% CO2 in
air, incubated at 37◦C[ 21]. 2 × 103 MBT cells in 100μL
of culture medium were seeded in 96-well plates and were
incubated for 24h at 37◦C. Cisplatin in vitro toxicity was
tested by adding serial dilutions of cisplatin in a volume of
10μL to the cultured MBT cells. Cytotoxicity of the polymer
degradation products was tested by adding 10μLs o l u t i o n
from the blank polymer release study (same sample used as a
blank control for the in vitro drug release). Cell proliferation
was estimated by 3H-thymidine incorporation [22]. All data
presented as mean ± STD of triplicate. The data was plotted
as a percentage of the data from the control cultures, which
were treated identically to the experimental cultures.
2.4. In Vivo Cisplatin Toxicity. In a separate study per-
formed to determine maximal tolerated dose (MTD) for
the cisplatin-polymer, mice were injected with increasing
doses of cisplatin incorporated in the polymer. The dose
of 25mg/kg was chosen as the treatment dose since it was
the maximal cisplatin dose at which mice did not show
weight loss throughout the study. The dose of 50mg/kg was
determined as (MTD) for cisplatin-polymer formulation,
because all mice survived but showed weight loss. The MTD
for intraperitoneal delivery was 5mg/kg, while LD50 for
cisplatin in C3H mice is 10mg/kg [6].
The experiments in mice were approved by the Ethical
Committee for Animal Experimentation of the Hebrew
University (NIH approval no. OPRR A01-5011).
2.5. In Vivo Antitumor Activity
2.5.1.InoculationofMBTCells. Inbred8–10-weekoldfemale
C3H mice, weighing about 20g (Harlan Laboratories, Israel)
were kept under speciﬁc pathogen-free (SPF) conditions
and given free access to irradiated food and acidiﬁed waterChemotherapy Research and Practice 3
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Scheme 1: Structure of poly(sebacic acid-co-ricinoleic acid).
throughout the experiment. Mice were injected subcuta-
neously via a 27-gauge needle in the posterolateral ﬂank
with 5 ×105 MBT cells suspended in 0.1mL RPMI medium.
Tumors were measured using caliper every other day, and
theirvolumeswerecalculatedbytheformula:length ×width
× height × 0.523.
2.5.2. Treatment Protocols. The treatment was initiated 10
days after tumor cells inoculation, when the tumor was
palpable,andthevolumerangewasbetween0.12–0.243cm3.
The mice were randomly assigned to one of the three
treatment groups or the two control groups (n = 10 in
each group). Mice in the control groups received either
intratumoral injection of 50μL of the blank polymer or no
treatment at all. The ﬁrst treatment group was injected with
50μL of a formulation containing 1% cisplatin in P(SA:RA)
2:8 (equivalent to 25mg/kg dose) intratumorally. The sec-
ondtreatmentgroup wastreatedwith intratumoral injection
of 0.1mL cisplatin solution in saline at a concentration of
1mg/mL which equals 5mg/kg, and the third group received
intraperitoneal (IP) injection of 0.1mL of cisplatin solution
in saline at a concentration of 1mg/mL (LD50 for cisplatin
in C3H mice is 10mg/kg). Mice received a single injection
duringtheexperiment. Theanimalsweresacriﬁcedwhenthe
tumor volume reached 3–3.5cm3.
2.6. Platinum Distribution in Plasma and Tissue. Additional
group of mice (n = 36) was injected with 5 × 105 MBT
cells to induce subcutaneous tumor. However, to determine
platinum distribution from the injection site in the tumor
mass, the treated tumors should partially escape from
the treatment; otherwise, there would be no tumor mass
to determine the platinum concentration. Thus, 50μLo f
the injectable polymer/cisplatin formulation containing 1%
cisplatin was injected 13 days after tumor cells inoculation
when the tumors volume was >1.2cm3. In this case the
tumor could not be totally eliminated, and the pattern
of platinum distribution in the tumor could be studied.
At diﬀerent time points (1, 2, 3, 5, 7, and 14 days after
injection), six mice were sacriﬁced. The tumor was excised
and frozen at 20◦C, and the blood was collected from cardiac
puncture, heparinized, and centrifuged (2500rpm, 5min)
to obtain plasma. The obtained plasma was separated and
kept frozen at 20◦C. Tissue samples were embedded (O.C.T.
Compound, Tissue-Tek, Redding, CA) and sectioned into
50–100-μm-thick sections in a cryostat at 20◦C. The sections
were weighed, decomposed in nitric acid, and diluted in
DDW to obtain 100-, 1000-, and 2200-fold dilutions to
determine platinum concentrations in solution and plasma
inICP-MS(PerkinElmer).Allsectionswereinspectedforthe
presence of nondegraded formulation, and the formulation
was manually scooped out to avoid biased calculation of the
actual drug concentration in the tissue.
2.7. Macroscopic and Histopathological Evaluation. For
histopathological evaluation animals were sacriﬁced 5 days
after treatment application, and tumors were dissected
and ﬁxed in 4% formaldehyde solution. The tissue was
processed into paraﬃn, and 3-μm sections were stained
with hematoxylin & eosin for histological evaluation.
The examination parameters included necrosis total area,
inﬂammatory cell inﬁltration, and intact tumor tissue.
2.8. Statistical Analysis. All results are expressed as mean
± standard deviation (STD) of the mean and statistically
analyzed using GraphPad Instat ANOVA. P values less than
.01 were considered signiﬁcant for all tests.
3. Results
3.1. In Vitro Cisplatin Release. The polymer carriers—
P(SA:RA) 2:8 and 3:7 having molecular weight (Mw)
ranging from 4000 to 6000Da were prepared from RA and
SA by melt condensation as previously described [17]. The
polymer structure is shown in Scheme 1. Incorporation of
5% w/w of cisplatin in the polymer by mixing at room
temperature did not aﬀect the molecular weight of the
polymer and had no chemical interaction with the polymer,
as was conﬁrmed by GPC and 1H-NMR. Cisplatin release
from P(SA:RA) had no initial burst eﬀect, and during the
ﬁrst day only 5–7% of the incorporated drug was released
(Figure 1), followed by additional 25% on the next day, and
reaching 85% in the following ten days.
3.2. In Vitro Cytotoxicity. Growth inhibition of cisplatin in
MBT cell culture is shown in Figure 2.T h eI C 50 value of
cisplatin was found to be 0.8μg/mL. Similar results of IC50
for cisplatin were reported earlier: 4.8μg/mL for MBT-2 cells
[6]a n d1 . 5μg/mL for Meth-AR-1 cells [7].
3.3. In Vivo Antitumor Activity. The eﬃcacy of cisplatin
delivered intratumorally was investigated in a heterotopic
mouse bladder tumor (MBT) model. The treatment was
initiated on the tenth day after tumor cell inoculation. Mice
that were not treated and mice injected with the blank
polymer were sacriﬁced 15 and 18 days, respectively, after4 Chemotherapy Research and Practice
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Figure 1: In vitro cumulative release of Pt from P(SA:RA)2:8
(triangles, dashed line) and P(SA:RA)3:7 (stars, solid line) loaded
with5%w/wcisplatin.Eachpointrepresentsthemeanvalue ±STD
(n = 3). Release was conducted in 0.1M phosphate buﬀer, pH 7.4,
at 37◦C. Pt concentrations were determined by ICP-MS.
0
10
20
30
40
50
60
70
80
90
100
02468 1 0
Pt concentration (mcg/mL)
C
e
l
l
p
r
o
l
i
f
e
r
a
t
i
o
n
i
n
h
i
b
i
t
i
o
n
(
%
)
Figure 2: In vitro inhibition eﬀect of cisplatin on MBT cells.
Cisplatin at increasing concentrations was added 24 hours after cell
incubation in wells.
tumor cells inoculation when the tumor volume exceeded
3.5cm3.However, the growth rate ofthe tumor wasslower in
mice injected with the blank polymer that caused statistically
signiﬁcant (P<. 005, ANOVA) delay in tumor progression
(Figure 3). The injection of blank polymer into the tumor
damaged its structure and delayed its development, but since
there was no therapeutic eﬀect on the tumor cells, as was
conﬁrmed in in vitro cultured cells, the tumor recovered
from the physical injury and continued to grow. The injected
dose of cisplatin was the same in intratumoral (IT) and
intraperitoneal (IP) injection of cisplatin solution (0.1% w/v
in saline, 0.1mL injection, 5mg/kg); however, IP delivered
drug-inhibited tumor growth more eﬃciently comparing to
IT application of solution. After IT injection of cisplatin
solution tumors reached the volume of 3cm3 13 days after
treatment while after IP treatment only after 16 days. Thus,
soluble cisplatin delivered in solution either IT or IP showed
eﬃciency compared to nontreatment and blank polymer
groups in prolonging mice life. In the cisplatin/polymer
group, mice were injected intratumorally with 50μL of the
1% cisplatin formulation 10 days posttumor inoculation.
In 8 mice out of 10 the tumors completely disappeared
during the ﬁrst 10 days after treatment, and mice remained
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
0 5 10 15 20 25 30 35
T
u
m
o
r
m
a
s
s
(
g
r
)
Time after treatment (days)
Cisplatin solution IT
Cisplatin solution IP
No treatment
Cisplatin 1% in polymer
P(SA-RA)2:8
Figure3:EﬀectofcisplatinonMBTtumorgrowthins.c.implanted
mice (n = 10). Cisplatin 1% w/w in polymer, 50μL( ∗:s o l i dl i n e ) ;
blank polymer (, dashed line); cisplatin solution (0.1% w/v in
saline, 100μL injection, 5mg/kg) (, dashed line) were injected
intratumorally. No treatment group is designated as () with solid
line, and the group treated IP with cisplatin solution (1% w/v in
saline, 100μL injection, 5mg/kg) is designated as () with solid
line. The tumor volume is expressed as mean ± STD. Statistically
signiﬁcant diﬀerences between the groups are signed with a star
(P<. 05, ∗).
tumorless till the end of the study (40 days posttumor cells
inoculation), while, in the other two mice in this treatment
group twenty days posttreatment administration, regrowth
of a small nodule at the edge of the original tumor appeared,
but its dimensions did not increase above 0.3cm3 till the end
of the study (40 days posttumor cells inoculation).
3.4.PlatinumTumorDistribution. Inthisstudywemeasured
total platinum levels rather than intact cisplatin. Cisplatin is
notstableinbiologicalﬂuidsandundergoesligand-exchange
reaction that result in metabolites with diﬀerent biological
activity. Although determining concentrations of both intact
cisplatin and its various metabolites would be a more
accurate way to predict its activity, measuring total serum
platinum is traditionally used for clinical pharmacokinetics
assays [8].
Platinum content in the tumor mass gradually decreased
over the time course of 14 days (Figure 4), while 90% of the
injected platinum was found in the tumor tissue 24 hours
aftertheinjectiondecreasingto12%oftheinjectedplatinum
at 14 days.
The peak platinum concentrations (Cmax)i nt u m o r
tissue at diﬀerent time points were deﬁned as the amount
of platinum per milligram tumor tissue excluding non-
degraded formulation (Figure 5). In the ﬁrst day after
injection, platinum concentration in the tumor tissue was
still low, which corresponded with the in vitro release results.
However, three days after the intratumoral injection, plat-
inum concentration was the greatest and reached 8.8μg/mg,
whileplatinumconcentrationinplasmawasonly0.12μg/ml.
Cmax gradually decreased in the following days, and 14
days after the injection platinum concentration in tumor
was 0.3μg/mg that is still high enough to induce cytotoxicChemotherapy Research and Practice 5
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Figure 4:Thetimeproﬁleofplatinumremaininginthetumorafter
intratumoral injection of cisplatin/polymer formulation (1% w/w,
50μL). Values are expressed as mean ± STD (n = 6).
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Figure 5: The time proﬁle of platinum maximal concentration
(Cmax) in the tumor tissue after intratumoral injection of cis-
platin/polymer formulation (1% w/w, 50μL). Values are expressed
as mean (n = 6).
eﬀect [23]. For comparison, systemic injection of 10mg/kg
free cisplatin produced tumor platinum concentration of
0.014μg/mg [24] ,w h i c hi sl o w e rt h a nCmax 14 days after
intratumoral injection of cisplatin/polymer formulation.
The cisplatin/polymer formulation was injected into the
center of the tumor; therefore, platinum distribution is
expected to be radial, while the greater concentrations are
found at the injection site with gradual decrease toward the
tumor boarder. Each line in Figure 6 represents platinum
concentration pattern at one time point from the center of
the tumor toward the edge over the distance in millimeters.
After 24 hours subsequent to injection, the maximal plat-
inum concentration of 1.1μg/mg tumor tissue was found
close to the injection site, and it decreased gradually to
0.01μg/mg at a distance of 4.4mm from the injection site
that is still considered above the therapeutic level. The
greatest platinum tumor tissue concentration was found at
3 and 4 days after the injection, reaching 8.8μg/mg and
3.8μg/mg, respectively. After 14 days, platinum levels at
the injection sites were still above the therapeutic level.
Interestingly, in the ﬁrst 4 days after the treatment, greater
gradient was observed between the injection site and the
distant areas of the tumor. However, at the later period,
the platinum content in the tumor tissue was more equally
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Figure 6: Cisplatin tumor tissue distribution after intratumoral
injection of cisplatin/polymer formulation (1% w/w, 50μL). Each
curve represents a diﬀerent time point when the mice were
sacriﬁced and their tumors processed. Values are expressed as mean
(n = 6).
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Figure 7: Platinum (Pt) levels in plasma. Pt levels in mice plasma
weredeterminedbyICP-MS.Eachdatapointrepresentstheaverage
of six mice ± STD.
distributed that can be explained by the drug diﬀusion and
the clearance from the injection site.
3.5. Platinum Plasma Levels. As reported elsewhere [6], the
plasma platinum levels after IV administration of free cis-
platin were11.7μg/mLattime zeroanddecreasedduring the
following 12 hours to 1μg/ml. After intratumoral injection
of cisplatin/polymer formulation platinum plasma levels
gradually increased from less than 0.1μg/mL after 24 hours
a n dp e a k e da t0 . 1 5 μg/mL on days 4–6, followed by sharp
decrease to 0.06μg/mL on day 8 (Figure 7). The platinum
plasma levels are closely related to the events occurring
in the tumor, where the polymer releases the incorporated
drug. Importantly, platinum plasma levels after intratumoral
polymer injection were several orders of magnitude lower
comparing to systemic delivery at all time points.
3.6. Macroscopic and Histopathological Evaluation. Figure 8
shows the macroscopic view of the tumors dissected from
mice and sectioned in cryostat. Figure 8(a) shows the MBT6 Chemotherapy Research and Practice
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Figure 8: Macroscopic view of frozen tumor tissues at cryostat sectioning: (a) tumor treated with cisplatin/polymer formulation and
excised 3 days after injection; (b) tumor treated with cisplatin/polymer formulation and excised 7 days after injection; (c) tumor treated
with the blank polymer and excised 3 days after injection; (d) untreated tumor. The polymeric formulation is assigned with the star (∗), the
necrotic tissue with the white circle (), the inﬁltration of the inﬂammation cells with a black circle (•), and the intact tumor cells with a
black rhomb ().
tumor treated with 50μL of 1% w/w cisplatin/polymer
formulation and removed 3 days after treatment. The for-
mulation’s color is yellow because of the cisplatin color and
can be easily recognized (designated as (∗), and contoured
withwhiteline).Threedaysafterformulationinjection,large
portion of the injected formulation was still found in the
center of the tumor tissue, and the formulation did not
totally degrade. A region of a reddish tissue surrounded
the injected formulation, which was histologically proven to
be a necrotic/inﬂammatory process (designated as ()a n d
contouredwithgreenline),followedbytheintacttumorcells
(designated as ()), as was proved in the histopathological
evaluation of the tissue. Seven days after the formulation
injection, 20% of platinum was still found in the tumor
tissue, but the formulation has already degraded, and the
injection site remained free of the polymer and tumor cells
(Figure 8(b)). Around the injection site, the necrotic region
increased in size, which applies to continuous cytotoxic
activity (designated as () and contoured with green line),
followed by the intact tumor cells (designated as ()). Blank
polymerwasinjectedintothetumorsandsectionedsimilarly
to eliminate the possibility of the blank polymer cytotoxic
activity. Figure 8(c) shows the tumor with the blank polymer
3 days after injection. The polymer region is surrounded by a
mild inﬂammation region followed by tumor cells, and while
partial eﬀect of the polymer on the tumor cells cannot be
excluded it was less vigorous than with cisplatin. For com-
parison, Figure 8(d) shows the tumor without treatment.
The changes appearing in the tumor tissue at the formu-
lation injection site and in more distant regions are shown in
the panoramic view of the histology images of the tumors
injected with cisplatin/polymer formulation (Figure 9(a)).Chemotherapy Research and Practice 7
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Figure 9:HistologyoftheMBTtumorinjectedintratumorallywith
cisplatin/polymer formulation (1% w/w, 50μL). (a) Magniﬁcation
×10, panoramic view of the slice; (b) magniﬁcation ×40, enlarge-
ment of the cisplatin/polymer region and the surrounding necrotic
area; (c) magniﬁcation ×40, enlargement of the border between
the end of the necrotic area and start of the intact tumor area; (d)
magniﬁcation ×40, enlargement of the intact tumor area beyond
the eﬀect of cisplatin. The polymeric formulation is assigned with
the star (∗), the necrotic tissue with the white circle (), the
inﬁltration of the inﬂammation cells with a black circle (•), and the
intact tumor cells with a black rhomb ().
Figure 10: Histology of nontreated MBT tumor (magniﬁcation
×40), intact tumor cells.
Only necrotic cells are present at the formulation-tumor
interface (higher magniﬁcation, Figure 9(b)). Along with the
necrosis progression, inﬂammation process is evident, and
theregionofdeadtumorcellsextendsupto3.5mmfromthe
cisplatin formulation. Figure 9(c) is a higher magniﬁcation
of a border region between the necrotic process and the
unaﬀected intact tumor tissue, followed by mainly tumor
cells (Figure 9(d)). The region in the tumor where cisplatin
did not diﬀuse and was below therapeutic dose (Figure 9(d))
has similar cells appearance as in the nontreated tumor
∗
0.1mm ×20
(a)
×40
(b)
Figure 11: Histology of the MBT tumor injected intratumorally
with blank polymer. (a) Magniﬁcation ×20; (b) magniﬁcation
×40, enlargement of the blank polymer and the surrounding mild
inﬂammation area; bar: 0.1mm; the polymeric formulation is
assigned with the star (∗), the necrotic tissue with the white circle
(),theinﬁltrationoftheinﬂammationcellswithablackcircle(•),
and the intact tumor cells with a black rhomb ().
(Figure 10). Importantly, tumor cells density became notice-
ablylowerinbothnecroticregionsandtheregionbeyondthe
border, which results in enhanced drug penetration and the
cytotoxic eﬀect [25]. Figure 11 shows the appearance of the
MBT tumor without treatment; no necrosis or inﬂammation
process was evident in the tumor tissue.
Eﬃcacy studies showed that intratumoral injection of a
blank polymer caused a delay in tumor growth (Figure 3).
Histological evaluation of the tumors injected with the blank
polymer revealed a mild inﬂammatory reaction and no
inﬁltration region around the polymer for 0.3mm. Beyond
the 0.3mm, intact tumor cells appear again, as shown in
Figures 11(a) and 11(b).
4. Discussion
The toxicity of conventional systemic cancer chemotherapy
has severely limited the safety and eﬀectiveness of such ther-
apy, and its impact on the quality of life of patients hampers8 Chemotherapy Research and Practice
its wider clinical application [8]. Plasma concentrations are
often used as a marker of cytotoxic exposure; however, drug
delivery to the tumor is determined not only by plasma
concentrations but also by distribution from plasma into the
extracellular ﬂuid (ECF) of the tumor and from the ECF into
the cells. Solid tumors have several potential barriers to drug
deliverythatmaylimitdrugpenetration,suchasalterationof
distribution of blood vessels, blood ﬂow, interstitial pressure,
and microcirculation in the tumor [23]. Therefore, high
systemic levels of the cytotoxic drug often cause systemic
toxicity without reaching eﬀective concentrations in the
tumor.
Various injectable drug delivery systems have been inves-
tigated for local delivery of cisplatin and other anticancer
agents. Intradose, a collagen gel, loaded with cisplatin and
epinephrine,hasbeenshowntobeeﬀectiveforthetreatment
of head and neck and hepatocellular cancers [26]. Intradose
is an injectable gel that releases cisplatin after intratumoral
injection. However, the semiliquid phase of the collagen gel
released its content in short time period of hours till couple
of days that evokes a need for repeated administrations.
Another injectable biodegradable PEG, PLGA polymer sys-
tem for intratumoral chemotherapy, is Atrigel. This system
has a similar drug release period; however, the solidiﬁcation
mechanism involves solvent displacement that can result
in higher systemic toxicity. Interestingly, platinum serum
levels in rats were 10times higher after Atrigel injection [8]
comparing to the mice serum levels reported in this study,
hence presenting lower systemic toxicity of the described
formulation combined with local eﬃciency again tumor
cells.
Poly(sebacicco-ricinoleicacid)2:8usedinthisstudyisa
hydrophobic polymer, built of natural fatty acids, which can
be used for the release of hydrophobic or hydrophilic drugs.
The polymeric paste formulation with cisplatin is injectable
through a 23-gauge needle and it forms a gel in contact with
body ﬂuids by a mechanism that does not involve solvent
leaching or temperature change [17, 18]. The purpose of
this study was to evaluate the eﬀect of cisplatin-polymer
formulation injected intratumorally in heterotopic model in
mice compared to immediate release formulation after IP
and IT delivery. Interestingly, we noticed that IP cisplatin
delivery delayed tumor growth more eﬃciently compared
to the same solution delivered IT. A possible explanation
of the superior eﬃciency in tumor treatment of IP delivery
is that the drug was delivered through the blood supply to
the tumor and had better chances reaching all the tumor
regions, while in the direct injection of cisplatin solution
to the tumor the delivery is limited to the injection site,
and cisplatin penetration can be inhibited by intratumoral
interstitial pressure [27]. Moreover, cisplatin in solution is
cleared almost immediately leaving other regions of the
tumor untreated. In contrast to IP or IT delivery of cisplatin
solution, the described polymeric formulation formed a
semisolid implant in situ as was conﬁrmed after tumor
excision and sectioning [18]. Because of the hydrophobic
nature of the polymer, there was no burst eﬀect upon
the formulation injection, and the drug was released at
controlled rate, as was determined by plasma platinum
levels monitoring. The levels of platinum in the tumors
treated with cisplatin/polymer formulation were above the
therapeutic threshold during two weeks after the injection,
without any signs of systemic toxicity. Importantly, incorpo-
rationofcisplatininthepolymerthatdeliveredthedrugover
prolonged period of time allowed increasing MTD 5 times
compared to immediate release formulation, hence injecting
25mg/kg in polymer versus only 5mg/kg in solution. Thus,
the eﬀectiveness of the polymeric formulation in treating
MBT tumor in the described heterotopic model can be the
result of higher dose, slow prolonged release and exposure
to the drug, and greater surface area of contact between the
tumor and the formulation.
Cisplatin is not stable in biological ﬂuids and under-
goes ligand-exchange reaction that results in aquated cis-
platin that gradually is transformed to other metabo-
lites through reaction with glutathione, albumin, and
nucleotides. Although both intact cisplatin and its metabo-
lites are biologically active, it is the intact cisplatin that
is responsible for nephrotoxicity. Thus, it can be assumed
that systemic platinum levels found after local delivery of
cisplatin in the polymer formulation are mainly in the form
of biological metabolites, rather than unmodiﬁed cisplatin,
because of the longer time cisplatin is exposed to biological
ﬂuids [24, 28].
Moreover, P(SA:RA) has been shown to be eﬀective in
treating solid tumors with paclitaxel, which is highly potent
hydrophobic chemotherapeutic drug [29, 30] .P( S A:R A ) -
based polymeric system is unique because it can serve as
a vehicle for delivery of both hydrophilic and hydrophobic
drugs concomitantly in a single injection, thus increasing the
therapeutic potential of the formulation [31–33].
5. Conclusion
The results of this work indicate that treatment with the
polymer formulation of cisplatin had a positive outcome
and inhibited the growth of the tumors. Distribution studies
of cisplatin after intratumoral injection showed high and
eﬀective concentrations in the tumors. Histological studies
proved the existence of the necrotic process caused by the
cytotoxic drug.
References
[1] K. A. Walter, R. J. Tamargo, A. Olivi et al., “Intratumoral
chemotherapy,” Neurosurgery, vol. 37, no. 6, pp. 1129–1145,
1995.
[2] D. H. Moore, “Chemotherapy for recurrent cervical carci-
noma,” Current Opinion in Oncology, vol. 18, no. 5, pp. 516–
519, 2006.
[3] C. A. Rabik and M. E. Dolan, “Molecular mechanisms of
resistance and toxicity associated with platinating agents,”
Cancer Treatment Reviews, vol. 33, no. 1, pp. 9–23, 2007.
[ 4 ]C .N .S t e r n b e r g ,S .M .D o n a t ,J .B e l l m u n te ta l . ,“ C h e m o t h e r -
apy for bladder cancer: treatment guidelines for neoadjuvant
chemotherapy, bladder preservation, adjuvant chemotherapy,
andmetastaticcancer,”Urology,vol.69,no.1,pp.62–79,2007.Chemotherapy Research and Practice 9
[5] S. Ramachandran, A. P. Quist, S. Kumar, and R. Lal, “Cisplatin
nanoliposomes for cancer therapy: AFM and ﬂuorescence
imaging of cisplatin encapsulation, stability, cellular uptake,
and toxicity,” Langmuir, vol. 22, no. 19, pp. 8156–8162, 2006.
[6] H. Uchino, Y. Matsumura, T. Negishi et al., “Cisplatin-
incorporating polymeric micelles (NC-6004) can reduce
nephrotoxicity and neurotoxicity of cisplatin in rats,” British
Journal of Cancer, vol. 93, no. 6, pp. 678–687, 2005.
[7] M. Konishi, Y. Tabata, M. Kariya et al., “In vivo anti-
tumor eﬀect through the controlled release of cisplatin from
biodegradable gelatin hydrogel,” J o u r n a lo fC o n t r o l l e dR e l e a s e ,
vol. 92, no. 3, pp. 301–313, 2003.
[8] F.A.Chen,M.A.Kuriakose,M.X.Zhou,M.D.DeLacure,and
R. L. Dunn, “Biodegradable polymer-mediated intratumoral
delivery of cisplatin for treatment of human head and neck
squamous cell carcinoma in a chimeric mouse model,” Head
and Neck, vol. 25, no. 7, pp. 554–560, 2003.
[9] D .T .T .Y app ,D .K.Llo y d,J .Zh u,andS.M.L ehnert,“ C isplatin
delivery by biodegradable polymer implant is superior to
systemic delivery by osmotic pump or i.p. injection in tumor-
bearing mice,” Anti-Cancer Drugs, vol. 9, no. 9, pp. 791–796,
1998.
[10] S.K.Dordunoo,A.M.C.Oktaba,W.Hunter,W.Min,T.Cruz,
and H. M. Burt, “Release of taxol from poly(ε-caprolactone)
pastes: eﬀect of water-soluble additives,” Journal of Controlled
Release, vol. 44, no. 1, pp. 87–94, 1997.
[11] R. Langer, “Biomaterials in drug delivery and tissue engi-
neering: one laboratory’s experience,” Accounts of Chemical
Research, vol. 33, no. 2, pp. 94–101, 2000.
[12] D. Teomim and A. J. Domb, “Fatty acid terminated polyanhy-
drides,” Journal of Polymer Science, Part A: Polymer Chemistry,
vol. 37, no. 16, pp. 3337–3344, 1999.
[13] D. Teomim, A. Nyska, and A. J. Domb, “Ricinoleic acid-based
biopolymers,” Journal of Biomedical Materials Research, vol.
45, no. 3, pp. 258–267, 1999.
[14] M. Hakkarainen, “Aliphatic polyesters: abiotic and biotic
degradation and degradation products,” Advances in Polymer
Science, vol. 157, pp. 113–138, 2002.
[15] D. S. Katti, S. Lakshmi, R. Langer, and C. T. Laurencin,
“Toxicity, biodegradation and elimination of polyanhydrides,”
Advanced Drug Delivery Reviews, vol. 54, no. 7, pp. 933–961,
2002.
[16] B. Vaisman, M. Motiei, A. Nyska, and A. J. Domb, “Bio-
compatibility and safety evaluation of a ricinoleic acid-based
poly(ester-anhydride) copolymer after implantation in rats,”
Journal of Biomedical Materials Research Part A,v o l .9 2 ,n o .2 ,
pp. 419–431, 2010.
[17] M.Y.Krasko,A.Shikanov,A.Ezra,andA.J.Domb,“Poly(ester
anhydride)s prepared by the insertion of ricinoleic acid into
poly(sebacic acid),” Journal of Polymer Science, Part A: Polymer
Chemistry, vol. 41, no. 8, pp. 1059–1069, 2003.
[18] A. Shikanov and A. Domb, “Poly(sebacic acid-co-ricinoleic
acid) biodegradable injectable in situ gelling polymer,”
Biomacromolecules, vol. 7, no. 1, pp. 288–296, 2006.
[19] M. Elkin, S. Ayesh, T. Schneider, N. De Groot, A. Hochberg,
and I. Ariel, “The dynamics of the imprinted H19 gene
expression in the mouse model of bladder carcinoma induced
by N-butyl-N-(4-hydroxybutyl)nitrosamine,” Carcinogenesis,
vol. 19, no. 12, pp. 2095–2099, 1998.
[20] S. Soncin, V. L. Cicero, G. Astori et al., “A practical approach
for the validation of sterility, endotoxin and potency testing
of bone marrow mononucleated cells used in cardiac regen-
eration in compliance with good manufacturing practice,”
Journal of Translational Medicine, vol. 7, pp. 1–9, 2009.
[ 2 1 ]E .S .Y .C h a n ,A .R .P a t e l ,A .K .S m i t he ta l . ,“ O p t i m i z i n g
Orthotopic Bladder Tumor Implantation in a Syngeneic
Mouse Model,” Journal of Urology, vol. 182, no. 6, pp. 2926–
2931, 2009.
[ 2 2 ] I .Y u d o v i n - F a r b e r ,N .B e y t h ,A .N y s k a ,E .I .W e i s s ,J .G o l e n s e r ,
and A. J. Domb, “Surface characterization and biocompati-
bility of restorative resin containing nanoparticles,” Biomacro-
molecules, vol. 9, no. 11, pp. 3044–3050, 2008.
[23] W. C. Zamboni, A. C. Gervais, M. J. Egorin et al., “isposition
of platinum (Pt) in B16 murine melanoma tumors after
administration of cisplatin or pegylated liposomal-cisplatin
formulations (SPI-077 and SPI-077B103),” Clinical Cancer
Research, vol. 6, no. 132, 2000.
[24] W. C. Zamboni, A. C. Gervais, M. J. Egorin et al., “Inter-
andintratumoraldispositionofplatinuminsolidtumorsafter
administration of cisplatin,” Clinical Cancer Research, vol. 8,
no. 9, pp. 2992–2999, 2002.
[25] H. J. Kuh, S. H. Jang, M. G. Wientjes, J. R. Weaver, and
J. L. S. Au, “Determinants of paclitaxel penetration and
accumulationinhumansolidtumor,” JournalofPharmacology
and Experimental Therapeutics, vol. 290, no. 2, pp. 871–880,
1999.
[26] T. J. Vogl, K. Engelmann, M. G. Mack et al., “CT-guided
intratumoural administration of cisplatin/epinephrine gel for
treatment of malignant liver tumours,” British Journal of
Cancer, vol. 86, no. 4, pp. 524–529, 2002.
[27] T. P. F. Gade, I. M. Buchanan, M. W. Motley, Y. Mazaheri, W.
M. Spees, and J. A. Koutcher, “Imaging intratumoral convec-
tion: pressure-dependent enhancement in chemotherapeutic
delivery to solid tumors,” Clinical Cancer Research, vol. 15, no.
1, pp. 247–255, 2009.
[28] W. C. Zamboni, A. C. Gervais, M. J. Egorin et al., “Systemic
and tumor disposition of platinum after administration of
cisplatin or STEALTH liposomal-cisplatin formulations (SPI-
077 and SPI-077 B103) in a preclinical tumor model of
melanoma,” Cancer Chemotherapy and Pharmacology, vol. 53,
no. 4, pp. 329–336, 2004.
[29] A. Shikanov, S. Shikanov, B. Vaisman, J. Golenser, and A.
J. Domb, “Paclitaxel tumor biodistribution and eﬃcacy after
intratumoral injection of a biodegradable extended release
implant,” International Journal of Pharmaceutics, vol. 358, no.
1-2, pp. 114–120, 2008.
[30] S. Shikanov, A. Shikanov, O. Gofrit, A. Nyska, B. Corn, and
A. J. Domb, “Intratumoral delivery of paclitaxel for treatment
of orthotopic prostate cancer,” Journal of Pharmaceutical
Sciences, vol. 98, no. 3, pp. 1005–1014, 2009.
[31] H. Nagai and Y. Sumino, “Therapeutic strategy of advanced
hepatocellular carcinoma by using combined intra-arterial
chemotherapy,” Recent Patents on Anti-Cancer Drug Discovery,
vol. 3, no. 3, pp. 220–226, 2008.
[32] V. R. Recinos, B. M. Tyler, K. Bekelis et al., “Combination
of intracranial temozolomide with intracranial carmustine
improves survivalwhen compared with eithertreatment alone
i nar o d e n tg l i o m am o d e l , ”Neurosurgery,v o l .6 6 ,n o .3 ,p p .
530–537, 2010.
[33] S. I. Sugiyama, Y. Yamashita, T. Kikuchi, Y. Sonoda, T.
Kumabe, and T. Tominaga, “Enhanced antitumor eﬀect
of combined-modality treatment using convection-enhanced
delivery of hydrophilic nitrosourea with irradiation or sys-
temic administration of temozolomide in intracranial brain
tumor xenografts,” Neurological Research,v o l .3 0 ,n o .9 ,p p .
960–967, 2008.